Week in Review: WuXi PharmaTech to List Subsidiary on China's Third Board

WuXi PharmaTech filed to list SynTheAll Pharmaceutical, its chemical drug manufacturing subsidiary, on China's Third Board, a two-year old OTC exchange; Fosun Pharma will pay $137 million to acquire a 65% sake in Suzhou Erye Pharma, an antibiotic company; CANbridge Life Sciences of Beijing raised $10 million in a Series A round from China investors; Oramed, an Israeli company that develops oral versions of IV drugs, raised $5 million from Guangxi Wuzhou Zhongheng; Sinopharm A-Think Pharma in-licensed China rights to a clinical-stage targeted cancer treatment from Aeterna Zentaris, a Canadian biotech; China Pioneer Pharma Holdings will distribute the cardiovascular drug Neoton in China for Alfa Wassermann of Italy; China has approved diagnostic test reagents for Ebola from three separate China companies; Eisai Co. of Japan completed construction of a new parenteral manufacturing plant in Suzhou; China RMB-denominated venture capital funds can contemplate making investments in foreign companies because China now allows them to convert RMB into foreign currencies; and a new IMS Health report says China is already the world's second largest pharmaceutical market with revenues expected to reach between $155 billion and $185 billion in 2018. More details.... Stock Symbols: (NYSE: WX) (SHA: 602196; HK; 2196) (NSDQ: ORMP) (SHA: 600252) (NSDQ: AEZS; TSX: AEZ) (TO: 4523) Share this with colleagues: // //  
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.